120885-31-6

Basic information

• Product Name: Quinoxaline, 2-methyl-7-nitro- (9CI)
• Synonyms: Quinoxaline, 2-methyl-7-nitro- (9CI)
• CAS NO: 120885-31-6
• Molecular Formula: C₉H₇N₃O₂
• Molecular Weight: 189.17078
• Product Categories: VARIOUSAMINE
• Mol File: 120885-31-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Quinoxaline, 2-methyl-7-nitro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Quinoxaline, 2-methyl-7-nitro- (9CI)(120885-31-6)
• EPA Substance Registry System: Quinoxaline, 2-methyl-7-nitro- (9CI)(120885-31-6)

Safety Data

• Hazardous Substances Data: 120885-31-6(Hazardous Substances Data)

Upstream product

• 131543-46-9 Glyoxal 
• 78-98-8 2-oxopropanal 
• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 102-69-2 tri-n-propylamine 
• 97-00-7 1-chloro-2,4-dinitro-benzene 
• 75077-45-1 2,4-dinitro-N-(prop-2-ynyl)aniline 
• 19801-10-6 2-hydroxy-3-methyl-6-nitroquinoxaline 
• 75306-12-6 2-chloro-3-methyl-6-nitroquinoxaline 
• 107426-02-8 2-hydrazino-3-methyl-6-nitroquinoxaline 
• 122457-25-4 2-(N-propargylamino)-5-nitroaniline 

Downstream Products

• 4236-41-3 3-methyl-6-aminoquinoxaline 
• 120885-34-9 5,6-diamino-3-methylquinoxaline 
• 122457-31-2 2-amino-8-methyl-3-trideuteromethylimidazo[4,5-f]quinoxaline 

Relevant articles and documents

Method for synthesizing quinoxaline compound under visible light induced iron catalysis condition

The invention belongs to the technical field of compound synthesis, and particularly relates to a method for synthesizing quinoxaline compounds under visible light induced iron catalysis conditions. The method comprises the following steps: by taking non-activated aliphatic amine and o-phenylenediamine as raw materials, under the action of a photosensitizer, under the illumination of visible light, reacting in a solvent at room temperature and under oxygen conditions to generate the quinoxaline compound. The method has better substrate universality and relatively mild reaction conditions, not only realizes synthesis of the quinoxaline compound for the first time, but also widens the field of organic synthesis.

New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models

Parkinson's disease (PD) is a neurodegenerative disorder of aging characterized by motor symptoms that result from the loss of midbrain dopamine neurons and the disruption of dopamine-mediated neurotransmission. There is currently no curative treatment for this disorder. To discover druggable neuroprotective compounds for dopamine neurons, we have designed and synthesized a second-generation of quinoxaline-derived molecules based on structure-activity relationship studies, which led previously to the discovery of our first neuroprotective brain penetrant hit compound MPAQ (5c). Neuroprotection assessment in PD cellular models of our newly synthesized quinoxaline-derived compounds has led to the selection of a better hit compound, PAQ (4c). Extensive in vitro characterization of 4c showed that its neuroprotective action is partially attributable to the activation of reticulum endoplasmic ryanodine receptor channels. Most interestingly, 4c was able to attenuate neurodegeneration in a mouse model of PD, making this compound an interesting drug candidate for the treatment of this disorder.

Novel highly regioselective syntheses of unsymmetrical 2,3-disubstituted quinoxalines

Non-symmetrical 2,3-disubstituted quinoxalines are not easily obtained in good yields because of the lack of regioselectivity of the Hinsberg condensation, or the large number of steps required for achieving their preparation. Two efficient methods leadin

Synthesis of the Food Mutagens MeIQx and 4,8-DiMeIQx by Copper(I) Promoted Quinoxaline Formation

The regiocontrolled syntheses of the title compounds (1 and 2) is described.The key step is a new intramolecular alkyne amination and aromatization process (5 6; 8 9) effected by tetrakis(acetonitrile)copper(I) tetrafluoroborate.

1,4,5,8-TETRA-AZAPHENANTHRENE COMPLEXES OF COPPER(I) AND SILVER(I)

Cu(I) and Ag(I) complexes of 1,4,5,8-tetra-azaphenanthrene (TAP) and of two its methylated derivatives (3,6-dimethyl- and 2,3,6,7-tetramethyl-) have been made and characterized.Their 1HNMR spectra are discussed.The structure of the complex Ag(TAP)2(NO3), as determined by X-Ray crystallography, is that of strongly folded and twisted square planar arrangement of the chelating ligands around the silver atom; the four Ag-N bonds are not equal: they are shorter (2.36 Angstroem) in one pair of trans bonds than in the other (2.56 Angstroem). 3,6-Dimethyl-1,4,5,8-tetra-azaphenanthrene (3,6dmTAP), a new TAP derivative, has been synthesized starting from 2-hydroxy-3-methylquinoxaline which was nitrated, then treated with POCl3, the resulting 2-chloro-3-methyl-6-nitroquinoxaline reacted with hydrazine and the hydrazino group oxidized to give 3-methyl-6-nitroquinoxaline.This was aminated with hydroxylamine, reduced to the diamine and finally condensed with glyoxal to give 2,6-dimethyl- and 3,6-dimethyl-1,4,5,8-tetra-azaphenanthrene.